BYSANTI
Mar 02, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
